Shares of Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT – Get Rating) have received a consensus recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the […]
Clarus Therapeutics Announces Closing of Upsized $30 0 Million Underwritten Public Offering streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Clarus Therapeutics Announces Pricing of Upsized $30 0 Million Underwritten Public Offering forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Analysts expect Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT – Get Rating) to announce ($0.86) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Clarus Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.13) and the highest estimate coming in at ($0.59). The business is […]
Analysts expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) to report earnings of ($0.86) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Clarus Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($1.13). The firm is scheduled to report its next earnings […]